Vitrolife ABOSTO:VITR +0.11%79 ROE % is 5.06% as of Mar. 2026, which is 47% below its 10-year median of 9.50. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 81.05% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vitrolife AB's annualized net income for the quarter that ended in Mar. 2026 was kr404 Mil. Vitrolife AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was kr7,982 Mil. Therefore, Vitrolife AB's annualized ROE % for the quarter that ended in Mar. 2026 was 5.06%.
The historical rank and industry rank for Vitrolife AB's ROE % or its related term are showing as below:
OSTO:VITR'
s ROE % Range Over the Past 10 Years
Min: -46.55 Med: 9.5 Max: 23.5
Current: -45.01
During the past 13 years, Vitrolife AB's highest ROE % was 23.50%. The lowest was -46.55%. And the median was 9.50%.
OSTO:VITR's ROE % is ranked worse than 81.05% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs OSTO:VITR: -45.01
Vitrolife AB (OSTO:VITR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vitrolife AB ROE % Related Terms
Vitrolife AB ROE % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's ROE % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Vitrolife AB (OSTO:VITR) has a ROE % of 5.06% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vitrolife AB and its competitors. This is 47% below median its historical median of 9.50. According to the industry distribution chart, Vitrolife AB ranks #646 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 81.1%.
Is Vitrolife AB's ROE % too high?
Vitrolife AB's current ROE % of 5.06% is 47% below median its 10-year median of 9.50. The Medical Devices & Instruments industry median ROE % is 2.40. Vitrolife AB's value of 5.06% is 110.8% above this industry median. Based on the distribution chart, Vitrolife AB ranks #646 out of 797 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #646 out of 797 companies for ROE %. This places Vitrolife AB in the lower half of its industry. The industry median ROE % is 2.40. Vitrolife AB's value of 5.06% is 110.8% above this benchmark. While the company's 10-year median is 9.50 vs. the industry median of 2.40, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current ROE % of 5.06% is 110.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current ROE % is 5.06%, which is 47% below median its own 10-year median of 9.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current ROE % is 5.06%, which is 47% below median its 10-year median of 9.50 and 110.8% above the Medical Devices & Instruments industry median of 2.40. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current ROE % is 5.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
ROE %: 5.06% (47% below median its 10-year median of 9.50)
GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
Industry Position: 110.8% above the Medical Devices & Instruments median (#646 of 797)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
